Emerging evidence indicates JAK inhibitors could be a valuable alternative for managing checkpoint inhibitor–induced immune ...

At 52 weeks, 20.6% of the upadacitinib group and 37.5% of the mycophenolate group had ≥ 5% absolute decline from baseline in FVC. A 10% drop in FVC from baseline at 1 year was also more common ...

The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, Fresenius Kabi, Hexal, Eli Lilly, Pfizer, Samsung Bioepis, Sanofi Aventis, ...

Other JAK inhibitors like tofacitinib (Xeljanz; Pfizer), baricitinib (Olumiant; Eli Lilly), upadacitinib (Rinvoq; AbbVie), and ritlecitinib (Litfulo; Pfizer) also show potential, though some, like ...

AbbVie claimed FDA approval for its JAK inhibitor Rinvoq (upadacitinib) for rheumatoid arthritis on Friday, setting its price just a little below that of its antibody blockbuster Humira. The once ...

Eli Lilly and Incyte's Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 ...

In recent years, JAK inhibitors have been developed for the treatment of various inflammatory and autoimmune diseases. This class of inhibitors comprises more than a dozen drugs, including tofacitinib ...

Upadacitinib was associated with the highest crude prevalence of acne (15.9%), followed by tofacitinib (4.3%) and filgotinib (1.9%). A dose-response relationship was identified for upadacitinib and ...

Patients with axSpA who received UPA reported rapid and sustained improvements in total and nocturnal back pain over 12 weeks.

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Rheumatoid arthritis drugs fight pain and prevent joint damage. See a full list of RA medications, including NSAIDs, DMARDs, immunosuppressants, and others.